Statement of Polish Respiratory Society and Polish Society of Allergology on the treatment of pulmonary complications in patients after SARS-CoV-2 infection

IF 0.2 Q4 ALLERGY

Alergologia Polska - Polish Journal of Allergology Pub Date : 2021-01-01 DOI:10.5114/pja.2021.109379

W. Piotrowski, A. Barczyk, A. Chciałowski, J. Chorostowska-Wynimko, M. Czajkowska-Malinowska, A. Kania, M. Kupczyk, K. Sładek, M. Kulus, P. Śliwiński

{"title":"Statement of Polish Respiratory Society and Polish Society of Allergology on the treatment of pulmonary complications in patients after SARS-CoV-2 infection","authors":"W. Piotrowski, A. Barczyk, A. Chciałowski, J. Chorostowska-Wynimko, M. Czajkowska-Malinowska, A. Kania, M. Kupczyk, K. Sładek, M. Kulus, P. Śliwiński","doi":"10.5114/pja.2021.109379","DOIUrl":null,"url":null,"abstract":"The aim of this document is to provide physicians treating patients with a history of COVID-19 pneumonia with recommendations on proper diagnostics and management of respiratory sequelae associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The expert panel provides 32 recommendations with respect to the treatment of lung consequences (including antibiotic therapy, corticosteroid therapy, and antithrombotic prophylaxis and treatment), pulmonary rehabilitation, lung transplantation, patient monitoring, and ambulatory settings. The management of patients with respiratory comorbidities (asthma, chronic obstructive pulmonary disease, lung cancer, and interstitial lung disease) and the medications used for treatment of these conditions, such as corticosteroids and antifibrotic drugs, is discussed. Presented recommendations are based on the most recent reports and aimed at providing patients post-COVID-19 respiratory sequelae with optimal standards of care.","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alergologia Polska - Polish Journal of Allergology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pja.2021.109379","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

The aim of this document is to provide physicians treating patients with a history of COVID-19 pneumonia with recommendations on proper diagnostics and management of respiratory sequelae associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The expert panel provides 32 recommendations with respect to the treatment of lung consequences (including antibiotic therapy, corticosteroid therapy, and antithrombotic prophylaxis and treatment), pulmonary rehabilitation, lung transplantation, patient monitoring, and ambulatory settings. The management of patients with respiratory comorbidities (asthma, chronic obstructive pulmonary disease, lung cancer, and interstitial lung disease) and the medications used for treatment of these conditions, such as corticosteroids and antifibrotic drugs, is discussed. Presented recommendations are based on the most recent reports and aimed at providing patients post-COVID-19 respiratory sequelae with optimal standards of care.

查看原文本刊更多论文

波兰呼吸学会和波兰过敏症学会关于SARS-CoV-2感染后肺部并发症治疗的声明

本文件旨在为治疗有COVID-19肺炎病史的医生提供关于正确诊断和管理与严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)感染相关的呼吸道后遗症的建议。专家小组就肺部后果的治疗(包括抗生素治疗、皮质类固醇治疗和抗血栓预防和治疗)、肺康复、肺移植、患者监测和门诊设置提供了32项建议。讨论了呼吸合并症(哮喘、慢性阻塞性肺病、肺癌和间质性肺疾病)患者的管理以及用于治疗这些疾病的药物，如皮质类固醇和抗纤维化药物。提出的建议以最新报告为基础，旨在为covid -19后呼吸道后遗症患者提供最佳护理标准。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alergologia Polska - Polish Journal of Allergology ALLERGY-

自引率

50.00%

发文量

期刊介绍： Alergologia Polska - Polish Journal of Allergology is aimed mainly at allergologists, but also medical doctors working in related fields, such as otolaryngology, pulmonology, and dermatology. The main goal of the journal is to ensure rapid publication of important research papers and interesting case studies from the following areas: allergology, diagnostics, therapy of allergic diseases, in particular in the area of immunotherapy, rhinitis, asthma. The Editorial Board accepts for publication original papers, case studies and letters to the Editor. We also publish review articles (both commissioned and those agreed upon with the Editor-in-Chief), articles dealing with standards of medical practice, as well as special issues. The journal is published quarterly. We guarantee short review times (up to two weeks) and immediate publication on-line upon Editor acceptance.